Effect of Freeze-Thawing Treatment on Platelet-Rich Plasma Purified with Different Kits

Int J Mol Sci. 2024 Sep 16;25(18):9981. doi: 10.3390/ijms25189981.

Abstract

Osteoarthritis of the knee (OAK), a progressive degenerative disease affecting quality of life, is characterized by cartilage degeneration, synovial inflammation, and osteophyte formation causing pain and disability. Platelet-rich plasma (PRP) is an autologous blood product effective in reducing OAK-associated pain. PRP compositions depend on their purification. In clinical practice, PRP is typically administered immediately after purification, while cryopreserved PRP is used in research. Platelets are activated by freezing followed by release of their humoral factors. Therefore, PRP without any manipulation after purification (utPRP) and freeze-thawed PRP (fPRP) may differ in their properties. We purified leukocyte-poor PRP (LPPRP) and autologous protein solution (APS) to compare the properties of utPRPs and fPRPs and their effects on OAK target cells. We found significant differences in platelet activation and humoral factor content between utPRPs and fPRPs in both LPPRP and APS. Freeze-thawing affected the anti-inflammatory properties of LPPRP and APS in chondrocytes and synovial cells differed. Both utPRPs and fPRPs inhibited polarization toward M1 macrophages while promoting polarization toward M2 macrophages. Freeze-thawing specifically affected humoral factor production in macrophages, suggesting that evaluating the efficacy of PRPs requires considering PRP purification methods, properties, and conditions. Understanding these variations may enhance therapeutic application of PRPs in OAK.

Keywords: autologous protein solution; macrophage polarization; osteoarthritis of the knee; platelet-rich plasma.

MeSH terms

  • Chondrocytes / metabolism
  • Cryopreservation / methods
  • Freezing*
  • Humans
  • Macrophages / metabolism
  • Male
  • Osteoarthritis, Knee / therapy
  • Platelet Activation
  • Platelet-Rich Plasma* / chemistry
  • Platelet-Rich Plasma* / metabolism

Grants and funding

The Japan Agency for Medical Research and Development funded this research (grant number, JP22bk0104156).